scispace - formally typeset
D

Don Poldermans

Researcher at Erasmus University Rotterdam

Publications -  464
Citations -  26669

Don Poldermans is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Perioperative & Myocardial infarction. The author has an hindex of 65, co-authored 464 publications receiving 25642 citations. Previous affiliations of Don Poldermans include Leiden University Medical Center.

Papers
More filters
Journal ArticleDOI

Outcome after mitral valve repair for acute and healed infective endocarditis

TL;DR: MVRep for mitral valve endocarditis is feasible with good clinical results, maintained valve competency with significant reductions in left atrial and left ventricular dimensions after surgery.
Journal ArticleDOI

Smoking Cessation has no Influence on Quality of Life in Patients with Peripheral Arterial Disease 5 Years Post-vascular Surgery

TL;DR: There was no effect of smoking cessation on QoL in PAD patients undergoing vascular surgery, given the link between smoking, complications and mortality in this patient group, and smoking cessation should be a primary target in secondary prevention.
Journal ArticleDOI

Methodological analysis of diagnostic dobutamine stress echocardiography studies.

TL;DR: An improvement of clinical relevance of DSE testing is possible by stronger adherence to common and new methodological standards, and methodological problems may explain the wide range in diagnostic variability.
Journal ArticleDOI

Mobile right heart thrombus and massive pulmonary embolism.

TL;DR: A patient with pulmonary embolism, treated unsuccessfully with heparin, revealed free-floating right heart thrombus and urgent surgical embolectomy was performed with relief of symptoms.
Journal ArticleDOI

Efficacy of zoniporide, an Na/H exchange ion inhibitor, for reducing perioperative cardiovascular events in vascular surgery patients.

TL;DR: The results fail to demonstrate the efficacy of zoniporide in reducing the proportion of patients at high risk undergoing noncardiac vascular surgery who experience a composite cardiovascular endpoint, which led the corporate sponsor to stop enrollment early on the basis of a futility analysis of the chance of demonstrating efficacy with a larger sample size.